AzTrials
AzTrials

Ph- Acute Lymphoblastic Leukemia (Ph-ALL)Phase 2Ph- ALL-2026NCT07643103

Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial

A Phase 2 study testing Inotuzumab Ozogamicin (IO), Venetoclax and Blinatumomab in people with Ph- Acute Lymphoblastic Leukemia (Ph-ALL), run by Institute of Hematology & Blood Diseases Hospital, China.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This is a prospective, open-label, single-arm, umbrella phase 2 clinical trial enrolling 32 adult patients with newly diagnosed Philadelphia chromosome-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL). Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Inotuzumab Ozogamicin (IO), Venetoclax and Blinatumomab
Could I receive a placebo?
No, everyone receives an active treatment
How many people
32 participants
Where
No sites listed yet
Study dates
12 Jun 2026to 31 May 2030
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Newly diagnosed adult (≥18 years) patients with Ph-negative B-cell acute lymphoblastic leukemia according to WHO 2022 criteria.
  • CD22-positive expression on tumor cells (CD22 ≥20%).
  • Expected survival ≥3 months.
  • Sexually active men and women of childbearing potential must agree to use effective contraception.
  • Ability to understand and voluntarily sign informed consent, and willingness to comply with study requirements. Informed consent must be signed by the patient or a legal next of kin prior to initiation of any study-specific procedures.

Who cannot join

  • Burkitt lymphoma/leukemia.
  • Acute leukemia of ambiguous lineage.
  • Pregnant women.
  • Severe, uncontrolled active infections.
  • History of chronic liver disease (e.g., liver cirrhosis) or prior veno-occlusive disease (VOD) / sinusoidal obstruction syndrome (SOS).
  • History of clinically significant ventricular arrhythmias, unexplained syncope (not vasovagal), or sinus node dysfunction or high-grade atrioventricular (AV) block with chronic bradycardia, unless a permanent pacemaker has been implanted.
Show all 9Show fewer
  • Uncontrolled active hepatitis B or hepatitis C infection, or known HIV seropositivity. HIV testing may be required according to local regulations or standards.
  • Psychiatric disorders that may impair the subject's ability to complete treatment or provide informed consent.
  • Any other conditions deemed by the investigator to render the subject unsuitable for participation in the study.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Ying Wang, MD, PhD contact

+86 22-23608095

wangying1@ihcams.ac.cn

About this study

Official title: A Prospective Umbrella Clinical Trial of Immuno-Targeted Agents Combined With Low-Dose Chemotherapy for Newly Diagnosed Adult Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

This is a prospective, open-label, single-arm, umbrella phase 2 clinical trial enrolling 32 adult patients with newly diagnosed Philadelphia chromosome-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL). All patients receive a frontline treatment backbone consisting of low-dose chemotherapy combined with immuno-targeted agents and a BCL2 inhibitor. Subsequent treatment pathways are guided by MRD response, disease characteristics, and clinical decision-making, including antibody-based immunotherapy, CAR-T cell therapy, or hematopoietic stem cell transplantation. All patients continue protocol-defined maintenance therapy after consolidation.

The primary endpoint is the complete remission rate with negative flow cytometric MRD after induction therapy. MRD is monitored longitudinally by flow cytometry, quantitative PCR, and immune repertoire sequencing. Safety is evaluated according to NCI CTCAE version 5.0.

Being tested
Inotuzumab Ozogamicin (IO), Venetoclax, Blinatumomab, CD19-directed chimeric antigen receptor (CAR-T) T cells, Vincristine

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Inotuzumab Ozogamicin (IO)Drug

    Anti-CD22 antibody-drug conjugate (ADC) administered intravenously during induction and consolidation therapy.

  • VenetoclaxDrug

    BCL-2 inhibitor administered orally daily during induction and consolidation cycles to enhance leukemic cell apoptosis.

  • BlinatumomabDrug

    CD19/CD3 bispecific T-cell engager (BiTE) administered as continuous intravenous infusion during consolidation therapy.

  • CD19-directed chimeric antigen receptor (CAR-T) T cellsBiological

    Autologous CD19 CAR-T cell therapy administered as a single intravenous infusion as optional consolidation therapy for eligible patients.

  • VincristineDrug

    A vinca alkaloid that inhibits microtubule formation by binding to tubulin, resulting in mitotic arrest and inhibition of proliferation of rapidly dividing leukemic cells.

  • CyclophosphamideDrug

    An alkylating agent that forms DNA cross-links, leading to inhibition of DNA replication and transcription and subsequent apoptosis of rapidly proliferating hematopoietic cells.

  • DexamethasoneDrug

    A synthetic glucocorticoid that induces lymphoid cell apoptosis and exerts anti-inflammatory and immunosuppressive effects, contributing to reduction of leukemic burden.

  • MethotrexateDrug

    A folate antimetabolite that inhibits dihydrofolate reductase, resulting in impaired DNA synthesis and cell replication, particularly in rapidly dividing lymphoid cells.

  • Cytarabine (Ara-C)Drug

    A pyrimidine nucleoside analog that inhibits DNA polymerase, leading to termination of DNA chain elongation and inhibition of leukemic cell proliferation.

  • PrednisoneDrug

    A glucocorticoid that induces apoptosis in lymphoid cells and provides anti-inflammatory and immunosuppressive effects as part of multi-agent leukemia therapy.

  • Mercaptopurine 50 mgDrug

    A purine analog antimetabolite that interferes with purine nucleotide synthesis and incorporates into DNA and RNA, inhibiting nucleic acid synthesis and cell proliferation.

Study groups in NCT07643103
Study groupRoleWhat they receive
Immuno-Targeted Therapy Plus Low-Dose ChemotherapyExperimentalAdult patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (Ph- B-ALL) receive frontline treatment with immuno-targeted agents, a BCL2 inhibitor, and low-dose chemotherapy. Induction therapy includes inotuzumab ozogamicin, venetoclax, vincristine, cyclophosphamide, and dexamethasone. Subsequent treatment is adapted according to measurable residual disease (MRD) response, antigen expression profile, and clinical condition, and may include blinatumomab-based immunotherapy, venetoclax-containing chemotherapy, CD19-directed CAR-T cell therapy, or hematopoietic stem cell transplantation. All patients proceed to protocol-defined maintenance therapy.
Receives: Drug: Inotuzumab Ozogamicin (IO); Drug: Venetoclax; Drug: Blinatumomab; Biological: CD19-directed chimeric antigen receptor (CAR-T) T cells; Drug: Vincristine; Drug: Cyclophosphamide; Drug: Dexamethasone; Drug: Methotrexate; Drug: Cytarabine (Ara-C); Drug: Prednisone; Drug: Mercaptopurine 50 mg

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Flow Cytometric MRD-Negative Complete Remission Rate

    Proportion of patients achieving complete remission (CR) with negative measurable residual disease (MRD) assessed by multiparameter flow cytometry after completion of induction therapy.

    Measured: At the end of induction therapy (approximately 1 month after treatment initiation)

Secondary outcomes (8)

  1. Next-Generation Sequencing (NGS)-MRD Negative Remission Rate

    Proportion of patients achieving MRD-negative remission assessed by immune repertoire sequencing.

    Measured: Within 3 months after treatment initiation

  2. Best MRD Clearance Rate

    Proportion of patients achieving the deepest MRD response during the first 3 months of treatment as assessed by flow cytometry, quantitative PCR, or immune repertoire sequencing.

    Measured: Within 3 months after treatment initiation

  3. Overall Survival (OS)

    Time from study enrollment to death from any cause.

    Measured: Up to 5 years

  4. Disease-Free Survival (DFS)

    Time from achievement of complete remission to relapse or death from any cause.

    Measured: Up to 5 years

  5. Relapse-Free Survival (RFS)

    Time from achievement of MRD-negative remission to hematologic relapse or death.

    Measured: Up to 5 years

  6. 30-Day Mortality

    Proportion of patients who die from any cause within 30 days after treatment initiation.

    Measured: 30 days

  7. 60-Day Mortality

    Proportion of patients who die from any cause within 60 days after treatment initiation.

    Measured: 60 days

  8. Incidence of Adverse Events

    Frequency, severity, and type of adverse events graded according to the National Cancer

    Measured: From treatment initiation through completion of study treatment, up to 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jun 2026
  2. Study start12 Jun 2026 (estimated)
  3. Primary completion31 May 2028 (estimated)
  4. Study completion31 May 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential
Masking
None (open label)
Enrolment
32 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07643103
Sponsor's protocol ID
IIT2026063
Other IDs
IIT2026063-EC-1
Acronym
Ph- ALL-2026
Status last verified
Jun 2026
First submitted
8 Jun 2026
Last updated
11 Jun 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Inotuzumab Ozogamicin (IO), Venetoclax and Blinatumomab in people with Ph- Acute Lymphoblastic Leukemia (Ph-ALL), run by Institute of Hematology & Blood Diseases Hospital, China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 11 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Ying Wang, MD, PhD (+86 22-23608095, wangying1@ihcams.ac.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Flow Cytometric MRD-Negative Complete Remission Rate (time frame: At the end of induction therapy (approximately 1 month after treatment initiation)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07643103.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in